Back to Search
Start Over
Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism.
- Source :
-
Atherosclerosis [Atherosclerosis] 2012 Jun; Vol. 222 (2), pp. 375-81. Date of Electronic Publication: 2012 Mar 27. - Publication Year :
- 2012
-
Abstract
- Revascularization procedures used for treatment of atherosclerosis often result in restenosis. Resveratrol (RSV), an antioxidant with cardiovascular benefits, decreases neointimal formation after arterial injury by a mechanism that is still not fully clarified. Our main objective was to address the role of nitric oxide synthases (NOSes) and more specifically the endothelial-NOS (eNOS) isoform as a mediator of this effect. RSV (4 mg/kg/day, s.c.) alone or in combination with the NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME) (2 mg/kg/day, s.c.) was given to Sprague-Dawley rats beginning at 3 days before arterial (carotid or aortic) injury. RSV reduced neointimal formation by 50% (P<0.01), decreased intimal cell proliferation by 37% (P<0.01) and reduced inflammatory markers such as PECAM and MMP-9 mRNA. These effects of RSV were all abolished by coadministration of l-NAME. Oral RSV (beginning at 5 days before arterial injury) reduced neointimal thickness after femoral wire injury in mice, however this effect was not observed in eNOS knockout mice. This is the first report of RSV decreasing neointimal cell proliferation and neointimal growth through an eNOS-dependent mechanism.<br /> (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Subjects :
- Administration, Oral
Animals
Aorta enzymology
Aorta injuries
Aorta pathology
Cardiovascular Agents administration & dosage
Carotid Arteries enzymology
Carotid Arteries pathology
Carotid Artery Injuries enzymology
Carotid Artery Injuries genetics
Carotid Artery Injuries pathology
Cell Proliferation drug effects
Disease Models, Animal
Enzyme Inhibitors pharmacology
Femoral Artery enzymology
Femoral Artery injuries
Femoral Artery pathology
Gene Expression Regulation
Male
Matrix Metalloproteinase 9 genetics
Mice
Mice, Inbred C57BL
Mice, Knockout
NG-Nitroarginine Methyl Ester pharmacology
Neointima
Nitric Oxide Synthase Type III antagonists & inhibitors
Nitric Oxide Synthase Type III deficiency
Nitric Oxide Synthase Type III genetics
Platelet Endothelial Cell Adhesion Molecule-1 genetics
RNA, Messenger metabolism
Rats
Rats, Sprague-Dawley
Resveratrol
Stilbenes administration & dosage
Time Factors
Vascular System Injuries enzymology
Vascular System Injuries genetics
Vascular System Injuries pathology
Aorta drug effects
Cardiovascular Agents pharmacology
Carotid Arteries drug effects
Carotid Artery Injuries drug therapy
Femoral Artery drug effects
Nitric Oxide Synthase Type III metabolism
Stilbenes pharmacology
Vascular System Injuries drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1879-1484
- Volume :
- 222
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Atherosclerosis
- Publication Type :
- Academic Journal
- Accession number :
- 22552115
- Full Text :
- https://doi.org/10.1016/j.atherosclerosis.2012.03.021